Axikin is a biopharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders. One program centers around a highly-validated molecular entity on leukocytes that are the primary cell types activated in the allergic response — eosinophils, basophils, mast cells and lymphocytes of the T helper type 2 lineage. The target is a 7-transmembrane G-protein coupled receptor (GPCR) whose activation is linked to cell migration and activation. Axikin scientists are now continuing to progress these lead candidates through pre-clinical IND-enabling studies.
Axikin also has two proprietary genomics targets in early discovery stages. One of these genes, a kinase, has been discovered following a microarray analysis of human lung tissue from patients with chronic obstructive lung disorder (COPD) and preliminary analyses have revealed a significant role for this gene in the production of highly relevant inflammatory mediators, and neutrophilic inflammation — a hallmark of the disease. This target will undergo further discovery analyses and testing to identify a small molecule therapeutic for COPD. Another proprietary target is a GPCR highly expressed in the lung and linked to pro-inflammatory activation and will continue to be developed with a goal of identifying small molecule antagonists for respiratory and inflammatory diseases.